ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 5, 2019

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Ovarian CancerAdnexal Mass
Interventions
DRUG

Method 1: Indocyanine green dye

Injection 4 mL of ICG dye directly into the fallopian tube (1 or more places is acceptable) only to the side where the adnexal mass is located

DRUG

Method 2: Indocyanine green dye

"1mL of ICG injected at each of the four sites: only to the side where the adnexal mass is located~* Dorsal side of the IP ligament~* Ventral side of the IP ligament~* Dorsal side of the utero-ovarian ligament~* Ventral side of the utero-ovarian ligament"

DRUG

Method 3: Indocyanine green dye

Injection of 2mL of ICG dye into the IP ligament pedicle after the adnexal mass has been removed. Only to the side where the adnexal mass is located

DRUG

Method 3: Indocyanine green dye

Injection of 2mL of ICG dye into the IP ligament pedicle before the adnexal mass is removed.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Consent only), Harrison

11553

Memorial Sloan Kettering Nassau (Consent only), Uniondale

11725

Memorial Sloan Kettering Commack (Consent only), Commack

07920

Memorial Sloan Kettering Basking Ridge (Consent only), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Consent only), Middletown

07645

Memorial Sloan Kettering Bergen (Consent only ), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER